This page is updated frequently with new Bowel-related patent applications.
|| List of recent Bowel-related patents
|Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis|
Described herein are methods and compositions related to inflammatory bowel disease. Specifically tl1a drives regional intestinal inflammation and fibrosis and is differentially modulated by ifn gamma and il-17a.
Cedars-sinal Medical Center
|Treatment of inflammatory bowel disease|
Wherein x, y, b, r2, r3, r4, r5, r6 and n have the meanings found herein.. .
|Combinations and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies|
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (ibd) such as crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with ibd a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (ccr9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab.
|Compositions containing omega-3 oil and uses thereof|
The invention provides pharmaceutical compositions containing omega-3 oil and a non-hydrophilic co-solvent that have an increased absorption rate. The pharmaceutical compositions may further contain one or more pharmaceutical organic molecules.
Maine Natural Health Company, Inc.
|Flow channel switching bidet nozzle|
The present invention relates a flow channel switching apparatus for bidet nozzle which is capable of providing a rectal injection function in addition to anus and genitalia cleaning which makes the bowel movement comfortable; of fluidly connecting the water tank and the drain hole to drain cold water supplied to prevent the water tank from overheating during initial stage of providing hot water and the final stage of the cleaning, even in a state where the water is not supplied to the anus cleaning hole, the genitalia cleaning hole, or the rectal injection hole, which allows reliable use of the bidet; and when the rotating plate is rotated to fluidly connect the supply through hole of the rotating plate and the anus cleaning hole, the genitalia cleaning hole, or the rectal injection hole penetrated through the disc valve, the supply through hole is fluidly connected to the respective supply hole to supply water, or either one of the first and the second drain through hole is fluidly connected to the discharge hole to guide water to be drained, which allows reliable use of bidet.. .
Nanutech Co., Ltd.
|Bicyclic derivative containing pyrimidine ring, and preparation method therefor|
The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-ht4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (gerd), constipation, irritable bowel syndrome (ibs), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like..
|Gelatin bowel prep with syringe for colonoscopy|
A purgative product is provided which includes a gelatinous purgative and a dispenser for dispensing the gelatinous purgative. The dispenser includes a container with an open end and an opening on the opposite end.
|Method for bowel preparation|
The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation.
Msm Innovations, Inc.
|Fermented food improving bowel functions with stercoral removal efficiency and manufacturing method thereof|
Exemplary embodiments of the present invention provide fermented foods improving bowel functions with stercoral removal efficiency and a manufacturing method thereof. The manufacturing method of the fermented foods improving bowel functions includes a first process in which herb powder and glasswort powder placed in a cloth pouch together are heated in a potable water, and a second process in which the previously heated mixture is fermented at 20-50° c.
|Compositions and methods for treating microbiota-related psychotropic conditions and diseases|
In alternative embodiments, the invention provides compositions and methods for treating, ameliorating and preventing various disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor, for example, where the microbial or bacterial flora of the bowel manufactures neurotoxins or neurotoxic agents that enter the body through the gastrointestinal (gi) tract, e.g. The colon, and reach the systemic space, e.g., by neural streaming or via the circulation, to reach the central nervous system (cns), including the brain, the peripheral nervous system (pns), and other nervous systems.
Method and kit for bowel preparation
The present invention provides methods and taste-modifying kits for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods and taste-modifying kits can improve patient compliance, and thus, efficacy of the preparation.
Msm Innovations, Inc.
Methods and compositions for determining relapse in inflammatory bowel disease
Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (ibd). Some embodiments include selecting a treatment for an evaluated ibd relapse risk in a subject..
Westfaelische Wilhelms-universitaet Muenster
Anti-il-25 antibodies and uses thereof
The present invention provides antibodies that bind to human interleukin-25 (il-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human il-25 with high affinity.
Regeneron Pharmaceuticals, Inc.
Hifu treatment optimization in vicinity of sensitive zones
The present invention provides a method for heating a target zone (3) of a subject of interest (1) according to pre-defined heating requirements using ultrasonic irradiation, comprising the steps of providing an ultrasonic irradiation device comprising a set of individually controllable transducer elements in vicinity of the target zone (3), defining at least one sensitive zone (2) within an area (4) covered by ultrasonic irradiation device, and controlling the ultrasonic irradiation device to apply sonications of ultrasonic energy to the target zone (3) to achieve the desired heating thereof, wherein the transducer elements are individually controlled in phase and amplitude to provide the sonications as a beam (5) directed towards the target zone (3), wherein the beam (5) has a energy distribution so that the pre-defined heating requirements of the target zone (3) are met and the exposure of the at least one sensitive zone (2) is minimized the present invention further provides an ultrasonic irradiation device adapted to perform the above method. By individually controlling the transducer elements, beam shaping of the ultrasonic irradiation can be applied over sensitive zones like scars, bones, bowels, spines or others without associating an intensity limit or energy exposure limit thereto.
Koninklijke Philips N.v.
Selective opioid compounds
Which relates to morphinan compounds useful as μ, δ and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.. .
New pyridopyrimidines derivatives compounds
Or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the camp and cgmp synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.. .
Gene signatures of inflammatory disorders that relate to the liver
This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (crohn's and ulcerative colitis).
Institut National De La Recherche Agronomique
The treatment of inflammatory disorders
The present invention provides nalidixic acid and analogues of nalidixic acid, and methods for treating inflammatory disorders. The nalidixic acid and analogues of nalidixic acid may be formulated for topical delivery or systemic delivery.
Cresset Biomolecular Discovery Ltd.
Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component
The present invention relates to an amidopyridinol derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including an amidopyridinol derivative or a pharmaceutically acceptable salt thereof as an active component. An amidopyridinol derivative represented by chemical formula 1 or a pharmaceutically acceptable salt thereof has an excellent antiangiogenic effect in a chorioallantoic membrane model, and thus is useful as an agent for preventing or treating diseases associated with angiogenesis, such as macular degeneration or arthritis, and also has an excellent colitis-inhibitory effect in a model of inflammatory bowel diseases, and thus is useful as an agent for preventing or treating inflammatory bowel diseases.
Research Cooperation Foundation Of Yeungnam University
Use of dietary fibre supplement in a food formulation
Use of dietary fibre material extracted from sugarcane in the manufacture of a food product that is formulated to ameliorate the effects of intestinal tract disorders such as coeliac's disease and irritable bowel syndrome (ibs).. .
Gratuk Technologies Pty Ltd
Miltefosin or perifosin for use in the treatment of ibd
Miltefosin or perifosin for use in the treatment or prevention of inflammatory bowel disease (ibd).. .
Academisch Medisch Centrum
Biomarkers for inflammatory bowel disease with ankylosing spondylitis
There is provided herein a method for categorizing a patient having inflammatory bowel disease as being at risk for developing ankylosing spondylitis. The method comprises the use of a patient level of auto-antibodies directed against noggin (nog) and/or sclerostin (sost) to determine a risk for the patient developing ankylosing spondylitis.
University Health Network
Kits for fecal neopterin concentration measurement as an indicator of disease activity in inflammatory bowel disease
Disclosed are methods for determining disease activity in a patient having or at risk for developing inflammatory bowel disease (ibd) which include measuring neopterin concentration in a fecal sample from the patient.. .
Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of tl1a inhibitors and/or dr3 inhibitors to an individual.
Cedars-sinai Medical Center
Use of salmonella flagellin derivative in preparation of drug for preventing and treating inflammatory bowel diseases
The application of flagellin derivative czlc31 from salmonella in preparation of medicines for preventing and treating inflammatory bowel disease (ibd) is introduced in this invention. The czlc331 protein has a good preventive and therapeutic effect for ibd, such as ulcerative colitis (uc) and crohn's disease (cd) in this invention.
Institute Of Radiation Medicine, Academy Of Military Medical Sciences, People's Lib
Use of pidotimod to treat irritable bowel syndrome
The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat irritable bowel syndrome. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally..
Use of pidotimod to treat inflammatory bowel disease
The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat inflammatory bowel disease. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally..
Biodegradable odor barrier film
A biodegradable odor barrier film for ostomy, continence and bowel management applications includes a barrier layer comprising at least about 90% wt. Polyglycolic acid.
Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services
Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (gnrh) receptor antagonists..
Bayer Pharma Aktiengesellschaft
Plant based formulation for the prevention and management of irritable bowel syndrome (ibs)
The invention relates to a plant based formulation for the prevention and management of irritable bowel syndrome (ibs) comprising of effective amount of a hydro-alcoholic extract of acacia arabica, aegle marmelos and nardostachys jatamansi.. .
Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants
The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (ibs-d), bile acid malabsorption, and the like..
Toilet with flushable overflow drain
A toilet with a flushable overflow drain includes a bowel and a primary drain connected to the bowel to receive fluid therefrom and having a primary drain trap. An overflow drain including an overflow drain trap is connected to the bowel at one end thereof and is connected at a second end to the primary drain at a location downstream of the primary drain trap.
The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis, inflammatory bowel disease or other inflammatory diseases, or renal failure. The invention further relates to a method for producing phosphatases..
Ras inhibitors and uses thereof
Described herein are compounds of formulae (i)-(ii), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject..
Dana-farber Cancer Institute, Inc.
Anti-methanogenic compositions and uses thereof
The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, irritable bowel syndrome (ibs). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines..
Cedars-sinai Medical Center
Probiotic strains for use in improving the enteric nervous system
The invention relates to the use of lactic acid bacteria, for use in modifying the enteric nervous system and more particularly in treating and/or preventing intestinal disorders such as constipation and/or irritable bowel disease.. .
Compagne Gervais Danone
Method and composition for treating inflammatory bowel disease without colectomy
Methods and compositions for treating diseased or damaged tissue, such as inflammatory bowel disease, e.g., ulcerative colitis, include tissue regeneration using stem cells or tissue grafts which stimulate stem cell migration to the damaged tissue. The tissue grafts can be extracellular matrix (ecm) material, such as tissue-specific extracellular matrix (ts-ecm).
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Novel polypeptides that bound to il-23 receptor and inhibit binding of il-23 and cell signaling thereof
The present invention relates to novel linear and cyclic polypeptides that bind to il-23 receptor and inhibit the binding of il-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of wx1x2x3w, where w is tryptophan, and x1, x2 and x3 are amino acids, with the proviso that when one of x1, x2 or x3 is w, the remaining two of x1, x2 or x3 cannot be w.
Medical Diagnostic Laboratories, Llc
Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
Wherein cy, l1, g, and r1 are as described herein. The present invention relates to novel compounds according to formula (i) that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g.
Provided are a compound expressed by formula (i) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [in the formula, a, x, y, z, r, and r1 have the meaning set forth in claim 1]..
Teijin Pharma Limited
Bowel topics: Bowel Disease, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Inflammation, Mercaptopurine, Probiotics, Abdominal Pain, Discomfort, Bowel Movement, Gastrointestinal, Ulcerative Colitis, Rheumatoid Arthritis, Jejunal Tube, Spring Mechanism, Small Bowel
Follow us on Twitter
This listing is a sample listing of patent applications related to Bowel for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bowel with additional patents listed. Browse our RSS directory or Search for other possible listings.